Orca Bio
Bringing Precision to Life
Menlo Park, United States · Founded 2016 · $567.0M raised
- Headquarters
- Menlo Park, California
- Employees
- 51–200
- Founded
- 2016
- Business Model
- B2B
- Website
- orcabio.com
- Total Funding
- $567.0M
- Last Round
- $250.0M Series FDec 2025
- Rounds
- 3
About
Orca Bio is a late-stage biotechnology company developing high-precision allogeneic T-cell immunotherapies for the treatment of cancer and autoimmune diseases. Its lead program, Orca-T, is designed to harness regulatory T cells to deliver durable remission with fewer risks than conventional stem cell transplants. The company has received FDA Priority Review for its Biologics License Application and completed a $250M aggregate financing in preparation for potential commercialization.
Summary
Orca Bio is a Biotech company based in Menlo Park, United States, founded in 2016. It has raised $567.0M in total across 3 rounds, most recently a $250.0M Series F round in Dec 2025. Investors include Lightspeed VP.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2025
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...